association

Full identifier: http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#association

Assigned to 1 class:

Minted in Nanopublication

 RAj1OdBZEz comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RAj1OdBZEz... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-08-25T14:13:30.145+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAj1OdBZEz... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAhNHZw6Ur... RAhNHZw6Ur .
This is the identifier for this whole nanopublication. http://purl.org/np/RAj1OdBZEz... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAj1OdBZEz... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-25T12:13:30.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Maprotiline hydrochloride tablets are contraindicated in patients hypersensitive to maprotiline and in patients with known or suspected seizure disorders. It should not be given concomitantly with monoamine oxidase (MAO) inhibitors. A minimum of 14 days should be allowed to elapse after discontinuation of MAO inhibitors before treatment with maprotiline is initiated. Effects should be monitored with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute phase of myocardial infarction.
Leoni Bücken
2021-08-25T12:13:30.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-25T12:13:30.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-25T12:13:30.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-25T12:13:30.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-25T12:13:30.145Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-25T12:13:30.145Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)